Finance

Beta
Ask
Lists
185750:KRX
Chong Kun Dang Pharmaceutical Corp
₩70,800.00
+1.43%
(+1,000.00) 1D
Jun 12, 3:30:26 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 185750...
Open
₩70,400
High
₩72,200
Low
₩70,200
Mkt. cap
977.24B
Avg. vol.
33.16K
Volume
0.00
Dividend
0.71%
Quarterly dividend
₩125
Ex-dividend date
Dec 29, 2025
P/E ratio
11.83
52-wk high
₩106,800
52-wk low
₩67,900
EPS
₩5,985
Shares outstanding
13.80M
No. of employees
2K
Open
₩70,400
High
₩72,200
Low
₩70,200
Mkt. cap
977.24B
Avg. vol.
33.16K
Volume
0.00
Dividend
0.71%
Quarterly dividend
₩125
Ex-dividend date
Dec 29, 2025
P/E ratio
11.83
52-wk high
₩106,800
52-wk low
₩67,900
EPS
₩5,985
Shares outstanding
13.80M
No. of employees
2K
News stories
From sources across the web
About Chong Kun Dang Pharmaceutical Corp
CEOYoung-Joo Kim
Employees2.25K
Founded1941
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
434.85B
429.82B
426.78B
447.77B
Cost of goods sold
298.49B
293.70B
296.28B
323.78B
Cost of revenue
298.49B
293.70B
296.28B
323.78B
Research and development expenses
41.06B
41.01B
35.34B
35.06B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
66.13B
69.14B
66.74B
68.78B
Operating expense
112.72B
115.13B
107.01B
109.90B
Total operating expenses
411.21B
408.83B
403.30B
433.68B
Operating income
23.64B
20.99B
23.48B
14.09B
Other non operating income
-413.83M
252.87M
363.50M
362.33M
EBT including unusual items
22.45B
20.81B
24.82B
13.70B
EBT excluding unusual items
21.98B
20.90B
23.93B
13.95B
Income tax expense
3.02B
576.67M
-1.47B
1.08B
Effective tax rate
13.47%
2.77%
-5.93%
7.90%
Other operating expenses
3.06B
2.80B
2.73B
3.80B
Net income
19.07B
20.10B
26.55B
12.82B
Net profit margin
4.38%
4.68%
6.22%
2.86%
Earnings per share
-
-
-
-
Interest and investment income
1.99B
1.25B
1.91B
1.80B
Interest expense
-1.86B
-1.19B
-1.81B
-2.28B
Net interest expenses
125.78M
58.24M
97.72M
-478.19M
Depreciation and amortization charges
1.37B
1.37B
1.33B
1.29B
EBITDA
34.64B
32.20B
34.88B
25.66B
Gain or loss from assets sale
328.00K
-25.05M
-515.84M
138.15M
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more